

# Gere Sunder-Plassmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6823505/publications.pdf>

Version: 2024-02-01

191  
papers

6,566  
citations

71102

41  
h-index

76900

74  
g-index

194  
all docs

194  
docs citations

194  
times ranked

5890  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. <i>Nature Medicine</i> , 2008, 14, 1088-1096.	30.7	420
2	Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. <i>European Heart Journal</i> , 2007, 28, 1228-1235.	2.2	320
3	High prevalence of hyperhomocysteinemia in critically ill patients. <i>Critical Care Medicine</i> , 2000, 28, 991-995.	0.9	286
4	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. <i>Journal of Medical Genetics</i> , 2017, 54, 288-296.	3.2	262
5	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 36.	2.7	239
6	Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey. <i>Acta Paediatrica</i> , <i>International Journal of Paediatrics</i> , 2006, 95, 86-92.	1.5	184
7	Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>PLoS Medicine</i> , 2014, 11, e1001750.	8.4	184
8	Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1323-1329.	6.1	174
9	Predialysis Serum Sodium Level, Dialysate Sodium, and Mortality in Maintenance Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2012, 59, 238-248.	1.9	145
10	Mutation analysis of <i>CD34</i> in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. <i>British Journal of Haematology</i> , 2001, 113, 357-364.	2.5	135
11	Dialysate Sodium Concentration and the Association with Interdialytic Weight Gain, Hospitalization, and Mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 92-100.	4.5	131
12	Anemia and Iron Deficiencies among Long-Term Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 794-797.	6.1	117
13	Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey. <i>Clinical Journal of Pain</i> , 2007, 23, 535-542.	1.9	115
14	Mutation (677C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. <i>Kidney International</i> , 1997, 52, 517-523.	5.2	112
15	Effect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1106-1116.	6.1	111
16	Significance of Interdialytic Weight Gain versus Chronic Volume Overload: Consensus Opinion. <i>American Journal of Nephrology</i> , 2013, 38, 78-90.	3.1	107
17	HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. <i>Kidney International</i> , 1995, 48, 1967-1971.	5.2	86
18	The effect of mild therapeutic hypothermia on renal function after cardiopulmonary resuscitation in men. <i>Resuscitation</i> , 2004, 60, 253-261.	3.0	80

#	ARTICLE	IF	CITATIONS
19	Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii41-ii50.	0.7	75
20	Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. <i>Kidney International</i> , 1998, 53, 1775-1782.	5.2	74
21	The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 60-69.	4.5	65
22	Prevalence of Uncontrolled Hypertension in Patients With Fabry Disease. <i>American Journal of Hypertension</i> , 2006, 19, 782-787.	2.0	64
23	A prospective study of anaemia and long-term outcomes in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3559-3566.	0.7	64
24	Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease. <i>American Journal of Nephrology</i> , 2009, 29, 353-361.	3.1	63
25	Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. <i>Kidney International</i> , 1999, 55, 1072-1080.	5.2	61
26	Citrate for long-term hemodialysis: Prospective study of 1,009 consecutive high-flux treatments in 59 patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 557-564.	1.9	60
27	C-Reactive Protein and Body Mass Index Independently Predict Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 1148-1154.	4.7	59
28	Effect of MTHFR 1298A>T and MTHFR 677C>T Genotypes on Total Homocysteine, Folate, and Vitamin B12 Plasma Concentrations in Kidney Graft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1918-1925.	6.1	57
29	Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1020-1029.	6.1	56
30	Increased serum activity of interleukin-2 in patients with pre-eclampsia. <i>Journal of Autoimmunity</i> , 1989, 2, 203-205.	6.5	51
31	Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 255-260.	6.1	51
32	Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. <i>Kidney International</i> , 1998, 54, 1637-1651.	5.2	50
33	Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Kidney International</i> , 2003, 63, 2280-2285.	5.2	46
34	Impairment of Transendothelial Leukocyte Migration by Iron Complexes. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2639-2644.	6.1	46
35	Sodium Setpoint and Sodium Gradient: Influence on Plasma Sodium Change and Weight Gain. <i>American Journal of Nephrology</i> , 2011, 33, 39-48.	3.1	46
36	Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. <i>Kidney International</i> , 2018, 93, 753-760.	5.2	46

#	ARTICLE	IF	CITATIONS
37	Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. American Journal of Kidney Diseases, 2000, 36, 1193-1200.	1.9	45
38	Simplified citrate anticoagulation for high-flux hemodialysis. American Journal of Kidney Diseases, 2001, 38, 979-987.	1.9	45
39	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2020, 131, 219-228.	1.1	44
40	Percentage of Hypochromic Red Blood Cells is an Independent Risk Factor for Mortality in Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 2075-2081.	4.7	43
41	Supraclavicular approach to the subclavian/innominate vein for large-bore central venous catheters. American Journal of Kidney Diseases, 1997, 30, 802-808.	1.9	41
42	Cinacalcet Decreases Bone Formation Rate in Hypercalcemic Hyperparathyroidism after Kidney Transplantation. American Journal of Nephrology, 2010, 31, 482-489.	3.1	41
43	Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Scientific Reports, 2019, 9, 13783.	3.3	41
44	Riboflavin Is a Determinant of Total Homocysteine Plasma Concentrations in End-Stage Renal Disease Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 1331-1337.	6.1	40
45	Cinacalcet Increases Calcium Excretion in Hypercalcemic Hyperparathyroidism After Kidney Transplantation. Transplantation, 2008, 86, 919-924.	1.0	40
46	Randomized, Single Blind, Controlled Trial to Evaluate the Prime-Boost Strategy for Pneumococcal Vaccination in Renal Transplant Recipients. PLoS ONE, 2012, 7, e46133.	2.5	40
47	Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. American Journal of Kidney Diseases, 2001, 37, 758-765.	1.9	39
48	A critical appraisal for definition of hyperfiltration. American Journal of Kidney Diseases, 2004, 43, 396.	1.9	39
49	Genetic determinants of the homocysteine level. Kidney International, 2003, 63, S141-S144.	5.2	38
50	Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. American Journal of Kidney Diseases, 2001, 38, 956-964.	1.9	36
51	Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transplant International, 2007, 20, 247-255.	1.6	35
52	Kidney transplantation in patients with Fabry disease. Transplant International, 2009, 22, 475-481.	1.6	35
53	An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. CKJ: Clinical Kidney Journal, 2019, 12, 333-337.	2.9	35
54	Molecular Genetics of Homocysteine Metabolism. Mineral and Electrolyte Metabolism, 1999, 25, 269-278.	1.1	34

#	ARTICLE	IF	CITATIONS
55	Effect of Glutamate Carboxypeptidase II and Reduced Folate Carrier Polymorphisms on Folate and Total Homocysteine Concentrations in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2003, 14, 1314-1319.	6.1	34
56	Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis, 2004, 174, 43-48.	0.8	34
57	Asymmetrical Dimethylarginine Plasma Concentrations Are Related to Basal Nitric Oxide Release but Not Endothelium-Dependent Vasodilation of Resistance Arteries in Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 1832-1838.	6.1	34
58	Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial. BMC Nephrology, 2017, 18, 238.	1.8	33
59	Evidence for an Increased Generation of Prostacyclin in the Microvasculature and an Impairment of the Platelet $\alpha$ -Granule Release in Chronic Renal Failure. Thrombosis and Haemostasis, 1988, 60, 205-208.	3.4	33
60	Dialysate Sodium Prescription and Blood Pressure in Hemodialysis Patients. American Journal of Hypertension, 2014, 27, 1160-1169.	2.0	32
61	Safety Aspects of Parenteral Iron in Patients with End-Stage Renal Disease. Drug Safety, 1997, 17, 241-250.	3.2	31
62	The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. European Journal of Echocardiography, 2011, 12, 744-749.	2.3	31
63	Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transplant International, 2009, 22, 287-292.	1.6	30
64	Dialysis and Transplantation in Fabry Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 379-385.	4.5	30
65	Anti-interleukin-1 $\alpha$ autoantibodies in hemodialysis patients. Kidney International, 1991, 40, 787-791.	5.2	29
66	Angiotensin converting enzyme DD genotype is associated with hypertensive crisis*. Critical Care Medicine, 2002, 30, 2236-2241.	0.9	29
67	Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study). Trials, 2013, 14, 196.	1.6	29
68	Malposition of a Dialysis Catheter in the Accessory Hemiazygos Vein. Anesthesia and Analgesia, 1996, 83, 883-885.	2.2	28
69	Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. American Journal of Kidney Diseases, 2004, 43, 1098-1103.	1.9	28
70	Potential risk for infection and atherosclerosis due to iron therapy. , 2005, 15, 105-110.		28
71	Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. Blood, 2001, 97, 2914-2915.	1.4	27
72	Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. American Journal of Kidney Diseases, 2001, 38, 77-84.	1.9	27

#	ARTICLE	IF	CITATIONS
73	Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients. <i>Kidney International</i> , 2003, 64, 1095-1100.	5.2	27
74	Endothelial Progenitor Cells in Kidney Transplant Recipients. <i>Transplantation</i> , 2006, 81, 599-606.	1.0	27
75	Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. <i>Kidney International</i> , 1999, 55, 2054-2061.	5.2	26
76	Effect of erythropoietin on cardiovascular diseases. <i>American Journal of Kidney Diseases</i> , 2001, 38, S20-S25.	1.9	26
77	Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 334-338.	1.9	26
78	Anemia is a new complication in Fabry disease: Data from the Fabry Outcome Survey. <i>Kidney International</i> , 2005, 67, 1955-1960.	5.2	24
79	History of Cardiovascular Disease Is Associated With Endothelial Progenitor Cells in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2005, 46, 520-528.	1.9	24
80	Reversibility of $\text{Ca}^{2+}$ Secondary Hypercalcitoninemia $\text{Ca}^{2+}$ After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1757-1763.	4.7	24
81	Results of an Ophthalmologic Screening Programme for Identification of Cases with Anderson-Fabry Disease. <i>Ophthalmologica</i> , 2004, 218, 207-209.	1.9	23
82	Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. <i>Kidney International</i> , 2005, 68, 2814-2822.	5.2	23
83	Safe and Efficient Emergency Transvenous Ventricular Pacing via the Right Supraclavicular Route. <i>Anesthesia and Analgesia</i> , 2000, 90, 784-789.	2.2	22
84	Effect of Hemodialysis Before Transplant Surgery on Renal Allograft Function—A Pair of Randomized Controlled Trials. <i>Transplantation</i> , 2009, 88, 1377-1385.	1.0	21
85	Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. <i>Transplant International</i> , 2012, 25, 680-686.	1.6	21
86	Employment Status and Associations with Workability, Quality of Life and Mental Health after Kidney Transplantation in Austria. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1254.	2.6	21
87	G-Protein $\beta 3$ subunit gene (GNB3) polymorphism 825C>T in patients with hypertensive crisis. <i>Critical Care Medicine</i> , 2000, 28, 3203-3206.	0.9	20
88	Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B12 in kidney transplant recipients. <i>Kidney International</i> , 2005, 67, 1980-1985.	5.2	20
89	Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta. <i>Molecular Genetics and Metabolism</i> , 2008, 95, 114-115.	1.1	20
90	Clinical evaluation of two novel bioactive PTH(1-84) assays in hemodialysis patients. <i>Clinical Biochemistry</i> , 2012, 45, 1645-1651.	1.9	20

#	ARTICLE	IF	CITATIONS
91	GBV-C/HCV in hemodialysis patients: Anti-E2 antibodies and GBV-C/HCV-RNA in serum and peripheral blood: mononuclear cells. <i>Kidney International</i> , 1998, 53, 212-216.	5.2	18
92	Renal function in heart failure: a disparity between estimating function and predicting mortality risk. <i>European Journal of Heart Failure</i> , 2013, 15, 763-770.	7.1	18
93	Urinary Total Globotriaosylceramide and Isoforms to Identify Women With Fabry Disease: A Diagnostic Test Study. <i>American Journal of Kidney Diseases</i> , 2011, 57, 673-681.	1.9	17
94	A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. <i>Transplant International</i> , 2007, 20, 505-511.	1.6	16
95	Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 79.	1.6	15
96	Upregulation of a lymphoid serine protease in kidney allograft recipients. <i>Kidney International</i> , 1990, 37, 1350-1356.	5.2	14
97	Comparative Look at Intravenous Iron Agents: Pharmacology, Efficacy, and Safety of Iron Dextran, Iron Saccharate, and Ferric Gluconate. <i>Seminars in Dialysis</i> , 1999, 12, 243-248.	1.3	14
98	Oral Sodium Bicarbonate Supplementation Does Not Affect Serum Calcification Propensity in Patients with Chronic Kidney Disease and Chronic Metabolic Acidosis. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 188-199.	2.0	14
99	Functional characterization of cytokine autoantibodies in chronic renal failure patients. <i>Kidney International</i> , 1994, 45, 1484-1488.	5.2	13
100	Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 519.	4.1	13
101	Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 1069-1073.	1.2	13
102	Effect of Oral Alkali Supplementation on Progression of Chronic Kidney Disease. <i>Current Hypertension Reviews</i> , 2015, 10, 112-120.	0.9	13
103	Two novel mutations in the $\beta$ subunit of the human epithelial sodium channel. <i>Kidney International</i> , 1999, 55, 2530-2531.	5.2	12
104	Effects of TCN2 776C>G on vitamin B12, folate, and total homocysteine levels in kidney transplant patients. <i>Kidney International</i> , 2004, 65, 1877-1881.	5.2	12
105	Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. <i>Kidney International</i> , 2004, 66, 295-302.	5.2	12
106	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. <i>Frontiers in Immunology</i> , 2021, 12, 720183.	4.8	12
107	Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. <i>Kidney International</i> , 2001, 59, 253-257.	5.2	12
108	Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. <i>Journal of Nephrology</i> , 2013, 26, 645-651.	2.0	12



#	ARTICLE	IF	CITATIONS
109	Patterns of co-occurrence of three single nucleotide polymorphisms of the 5,10-methylenetetrahydrofolate reductase gene in kidney transplant recipients. <i>European Journal of Clinical Investigation</i> , 2004, 34, 613-618.	3.4	11
110	Parathyroid Hormone Secretion During Citrate Anticoagulated Hemodialysis in Acutely Ill Maintenance Hemodialysis Patients. <i>Anesthesia and Analgesia</i> , 2004, 99, 1199-1204.	2.2	11
111	Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. <i>Kidney International</i> , 2005, 68, 2857-2862.	5.2	11
112	Prognostic Associations Between Lipid Markers and Outcomes in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 509-517.	1.9	11
113	Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis. <i>Kidney International</i> , 2010, 77, S8-S11.	5.2	11
114	A SAGE based approach to human glomerular endothelium: defining the transcriptome, finding a novel molecule and highlighting endothelial diversity. <i>BMC Genomics</i> , 2014, 15, 725.	2.8	11
115	A pharmacological chaperone on the horizon. <i>Nature Reviews Nephrology</i> , 2016, 12, 653-654.	9.6	11
116	Hyperhomocysteinemia in organ transplantation. <i>Current Opinion in Urology</i> , 2000, 10, 87-94.	1.8	10
117	Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. <i>Kidney International</i> , 2001, 59, S253-S257.	5.2	10
118	Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. <i>Kidney International</i> , 2002, 61, 1894-1898.	5.2	10
119	Impact of Measures to Enhance the Value of Observational Surveys in Rare Diseases: The Fabry Outcome Survey (FOS). <i>Value in Health</i> , 2011, 14, 862-866.	0.3	10
120	C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 247.	2.7	10
121	Laboratory diagnosis of anaemia in dialysis patients: use of common laboratory tests. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 566-569.	2.0	9
122	Morbus Fabry in Österreich. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 235-240.	1.9	9
123	Iron overload in kidney transplants: Prospective analysis of biochemical and genetic markers. <i>Kidney International</i> , 2005, 67, 691-697.	5.2	9
124	Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2015, 28, 679-689.	2.0	9
125	Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency. <i>Journal of the Neurological Sciences</i> , 2017, 383, 123-127.	0.6	9
126	Migalastat for the treatment of Fabry disease. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 301-309.	0.8	9



#	ARTICLE	IF	CITATIONS
127	Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. CKJ: Clinical Kidney Journal, 2020, 13, 225-234.	2.9	9
128	The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans. Journal of Clinical Medicine, 2020, 9, 2640.	2.4	9
129	Quantification of Î±-galactosidase activity in intact leukocytes. Clinica Chimica Acta, 2010, 411, 1666-1670.	1.1	8
130	Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy. International Journal of Medical Sciences, 2016, 13, 340-346.	2.5	8
131	Molecular Analysis of the Carboxy Terminus of the Beta and Gamma Subunits of the Epithelial Sodium Channel in Patients with End-Stage Renal Disease. Nephron, 1999, 81, 381-386.	1.8	7
132	Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells?. Kidney International, 2001, 59, S258-S261.	5.2	7
133	Genetic Aspects of Hyperhomocysteinemia in Chronic Kidney Disease. Seminars in Nephrology, 2006, 26, 8-13.	1.6	7
134	Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients. Clinical Biochemistry, 2014, 47, 1316-1319.	1.9	7
135	Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial. Trials, 2015, 16, 182.	1.6	7
136	Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients. European Journal of Internal Medicine, 2020, 73, 51-58.	2.2	7
137	Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy. Kidney Medicine, 2020, 2, 213-217.	2.0	7
138	100 years of inherited metabolic disorders in Austriaâ€”A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. Journal of Inherited Metabolic Disease, 2022, 45, 144-156.	3.6	7
139	Percutaneous Nonangiographic Insertion of Hickman Catheters in Marrow Transplant Recipients by Anesthesiologists and Intensivists. Anesthesia and Analgesia, 1997, 84, 80-84.	2.2	6
140	Radiological Screening for Hickman Catheter Insertion. Anesthesia and Analgesia, 1998, 86, 216-217.	2.2	6
141	Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis. Transplant Immunology, 2008, 20, 14-20.	1.2	6
142	Effect of Conversion From Cyclosporin to Tacrolimus on Endothelial Progenitor Cells in Stable Long-Term Kidney Transplant Recipients. Transplantation, 2013, 95, 1338-1345.	1.0	6
143	Exclusion of pregnancy in dialysis patients: diagnostic performance of human chorionic gonadotropin. BMC Nephrology, 2020, 21, 70.	1.8	6
144	Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomainsâ€”Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. Covid, 2021, 1, 105-114.	1.5	6

#	ARTICLE	IF	CITATIONS
145	Central Venous Catheterization in a Patient in the Prone Position. <i>Critical Care Medicine</i> , 1997, 25, 1439-1440.	0.9	6
146	First case of atypical haemolytic uremic syndrome following Covid-19 vaccination with BNT162b2. <i>Clinical Kidney Journal</i> , 0, , .	2.9	6
147	Pathophysiology and Clinical Importance of Hyperhomocysteinemia: Clinical Intervention Studies. <i>Mineral and Electrolyte Metabolism</i> , 1999, 25, 286-290.	1.1	5
148	Iron Therapy in Renal Transplant Recipients. <i>Transplantation</i> , 2004, 78, 1239-1240.	1.0	5
149	Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 964.	2.4	5
150	COVID-19 serology in nephrology healthcare workers. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 923-930.	1.9	5
151	A Coincidence of Disastrous Accidents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 43, 556-557.	2.4	5
152	TGF-beta1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. <i>Transplant International</i> , 2003, 16, 843-848.	1.6	4
153	Cardiovascular Disease Mortality in Kidney Transplant Recipients: No Light at the End of the Tunnel?. <i>American Journal of Kidney Diseases</i> , 2012, 59, 754-757.	1.9	4
154	Agreement of dried blood spot lyso-Gb3 concentrations obtained from different laboratories in patients with Fabry disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e275-e278.	2.3	4
155	Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron. <i>Viruses</i> , 2022, 14, 1181.	3.3	4
156	Exercise Chronotropy in Patients with Normal and Impaired Sinus Node Function After Cardiac Transplantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993, 16, 1793-1799.	1.2	3
157	Approaching the End of the Homocysteine Hype?. <i>American Journal of Kidney Diseases</i> , 2008, 51, 549-553.	1.9	3
158	Ecuzumab use in a tertiary care nephrology center: data from the Vienna TMA cohort. <i>Journal of Nephrology</i> , 2022, 35, 451-461.	2.0	3
159	MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease. <i>Genes</i> , 2021, 12, 1184.	2.4	3
160	Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0135674.	2.5	3
161	The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. <i>Clinical Laboratory</i> , 2016, 62, 1965-1972.	0.5	3
162	Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1087-1093.	3.4	2

#	ARTICLE	IF	CITATIONS
163	SP730PREEMPTIVE PLASMA THERAPY AND ECULIZUMAB RESCUE FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME RELAPSE FOLLOWING KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2018, 33, i592-i593.	0.7	2
164	A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes. PLoS ONE, 2019, 14, e0218709.	2.5	2
165	Pregnancies in kidney transplant recipients with complement gene variant-mediated thrombotic microangiopathy. CKJ: Clinical Kidney Journal, 2021, 14, 1255-1260.	2.9	2
166	Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, CJN.03850321.	4.5	2
167	Can Hemodialysis Technique Modify the Hypercatabolic State?. Renal Failure, 1996, 18, 395-404.	2.1	1
168	Underuse of Hardy-Weinberg equilibrium. Kidney International, 2004, 66, 1711.	5.2	1
169	No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 390-396.	3.1	1
170	Fabry Disease. , 2014, , 381-387.		1
171	FO021ORAL SODIUM BICARBONATE SUPPLEMENTATION DOES NOT AFFECT SERUM CALCIFICATION PROPENSITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND CHRONIC METABOLIC ACIDOSIS. Nephrology Dialysis Transplantation, 2018, 33, i9-i10.	0.7	1
172	SP046EFFECT OF SODIUM BICARBONATE LOAD ON 24-HOUR AMBULATORY BLOOD PRESSURE MEASUREMENTS IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE: PRELIMINARY RESULTS OF THE SOBIC STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	1
173	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2019, 126, S53.	1.1	1
174	Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis. Frontiers in Medicine, 2021, 8, 711034.	2.6	1
175	Fabry Disease Case Finding Studies in High-Risk Populations. , 2010, , 153-162.		1
176	Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease. Orphanet Journal of Rare Diseases, 2022, 17, 37.	2.7	1
177	Permanent Catheters Damaged by Power Injection of Contrast Media. Journal of Parenteral and Enteral Nutrition, 1995, 19, 428-428.	2.6	0
178	TGF- $\beta$ 1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. Transplant International, 2002, 16, 843-848.	1.6	0
179	Automated Fluorescence Polarization Immunoassay for Measurement of Increased Total Homocysteine Plasma Concentrations in Hemodialysis Patients. Laboratory Medicine, 2003, 34, 538-542.	1.2	0
180	Therapy of Fabry disease. Kidney International, 2004, 66, 1288.	5.2	0

#	ARTICLE	IF	CITATIONS
181	Response of patients with Fabry disease with the amenable GLA mutation p.N215S to treatment with migalastat. Molecular Genetics and Metabolism, 2017, 120, S68-S69.	1.1	0
182	Relationship between CFHR5 and complement parameters in patients suffering from complement-mediated kidney disorders, with or without CFHR5 mutations. Molecular Immunology, 2017, 89, 177.	2.2	0
183	FP714LONG-TERM NEURODEVELOPMENTAL AND ANTHROPOMETRICAL OUTCOME OF CHILDREN BORN TO FEMALE KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2018, 33, i286-i286.	0.7	0
184	SP007EARLY FETAL OUTCOME OF 28 PREGNANCIES IN WOMEN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME. Nephrology Dialysis Transplantation, 2018, 33, i348-i349.	0.7	0
185	Assessment of the C3b- and iC3b-binding ability of CFHR5 variants. Molecular Immunology, 2018, 102, 141.	2.2	0
186	First case of late onset cardiac phenotype Fabry disease due to an AluYb8 insertion in exon 7 of the GLA gene. European Heart Journal Cardiovascular Imaging, 2019, 20, 1182-1182.	1.2	0
187	Design of a prospective, multicenter, multinational, observational safety and outcomes registry in Fabry disease patients treated with migalastat and untreated patients. Molecular Genetics and Metabolism, 2019, 126, S140-S141.	1.1	0
188	Clinical outcomes after switching to migalastat from agalsidase alfa or agalsidase beta in patients with Fabry disease: Post hoc analysis from ATTRACT. Molecular Genetics and Metabolism, 2019, 126, S141.	1.1	0
189	Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report. Case Reports in Obstetrics and Gynecology, 2019, 2019, 1-7.	0.3	0
190	P0179ECULIZUMAB USE IN A TERTIARY CARE NEPHROLOGY CENTER. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
191	Homocysteine and atherosclerosis in dialysis patients. , 2004, , 809-827.		0